Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1
36
about 6.1 years
18+
1 site in CA
About this study
This trial is testing a new treatment called anti-CD19 CAR-T cells to see if it's safe and can be used in people with relapsed or refractory non-Hodgkin lymphoma. The treatment involves genetically modifying T cells to target the CD19 protein on B cells.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive anti-CD19 CAR-T cells
- 2.Take Cyclophosphamide
- 3.Take Fludarabine
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, cell therapy (Engineered T-cells that target specific cancer antigens)
infusion
Primary: Proportion of participants who experience a dose-limiting toxicity (DLT) (Dose escalation), Proportion of participants with treatment-emergent adverse events (AEs)
Secondary: Complete Response Rate, Median Overall Survival, Median Progression-free Survival (PFS), Median duration of response, Overall Response Rate (ORR), Partial Response Rate, Proportion of participants with CAR-T infusion related adverse events (Dose Escalation), Proportion of participants with delayed infusion due to study-related adverse events
Oncology